Literature DB >> 3546369

Significance of quantitative enzyme-linked immunosorbent assay (ELISA) results in evaluation of three ELISAs and Western blot tests for detection of antibodies to human immunodeficiency virus in a high-risk population.

P Nishanian, J M Taylor, E Korns, R Detels, A Saah, J L Fahey.   

Abstract

The characteristics of primary (first) tests with three enzyme-linked immunosorbent assay (ELISA) kits for human immunodeficiency virus (HIV) antibody were determined. The three ELISAs were performed on 3,229, 3,130, and 685 specimens from high-risk individuals using the Litton (LT; Litton Bionetics Laboratory Products, Charleston, S.C.), Dupont (DP; E. I. du Pont de Nemours & Co., Inc., Wilmington, Del.), and Genetic Systems (GS; Genetic Systems, Seattle, Wash.) kits, respectively. Evaluation was based on the distribution of quantitative test results (such as optical densities), a comparison with Western blot (WB) results, reproducibility of the tests, and identification of seroconverters. The performances of the GS and the DP kits were good by all four criteria and exceeded that of the LT kit. Primary ELISA-negative results were not always confirmed with repeat ELISA and by WB testing. The largest percentage of these unconfirmed negative test results came from samples with quantitative results in the fifth percentile nearest the cutoff. Thus, supplementary testing was indicated for samples with test results in this borderline negative range. Similarly, borderline positive primary ELISA results that were quantitatively nearest (fifth percentile) the cutoff value were more likely to be antibody negative on supplementary testing than samples with high antibody values. In this study, results of repeated tests by GS ELISA showed the least change from first test results. DP ELISA showed more unconfirmed primary positive test results, and LT ELISA showed more unconfirmed primary negative test results. Designation of a specimen with a single ELISA quantitative level near the cutoff value as positive or negative should be viewed with skepticism. A higher than normal proportion of specimens with high negative optical densities by GS ELISA (fifth percentile nearest the cutoff) and also negative by WB were found to be from individuals in the process of seroconversion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3546369      PMCID: PMC265907          DOI: 10.1128/jcm.25.2.395-400.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV).

Authors:  J S McDougal; S P Cort; M S Kennedy; C D Cabridilla; P M Feorino; D P Francis; D Hicks; V S Kalyanaraman; L S Martin
Journal:  J Immunol Methods       Date:  1985-01-21       Impact factor: 2.303

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Evaluation of eight ELISA kits for the detection of anti-LAV/HTLV-III antibodies.

Authors:  A M Courouce
Journal:  Lancet       Date:  1986-05-17       Impact factor: 79.321

4.  Evaluation of commercial AIDS screening test kits.

Authors:  J R Carlson; S H Hinrichs; N B Levy; M B Gardner; P Holland; N C Pedersen
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

5.  HLA DR4 antibodies cause positive HTLV-III antibody ELISA results.

Authors:  P Kühnl; S Seidl; G Holzberger
Journal:  Lancet       Date:  1985-05-25       Impact factor: 79.321

6.  Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications.

Authors:  S H Weiss; J J Goedert; M G Sarngadharan; A J Bodner; R C Gallo; W A Blattner
Journal:  JAMA       Date:  1985-01-11       Impact factor: 56.272

7.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

8.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  8 in total

1.  Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression.

Authors:  E Ojo-Amaize; P G Nishanian; D F Heitjan; A Rezai; I Esmail; E Korns; R Detels; J Fahey; J V Giorgi
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

2.  Antibody that inhibits human immunodeficiency virus reverse transcriptase and association with inability to isolate virus.

Authors:  K Sano; M H Lee; F Morales; P Nishanian; J Fahey; R Detels; D T Imagawa
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

3.  Utility of quantitative enzyme immunoassay reactivity for predicting human immunodeficiency virus seropositivity in low- and high-prevalence populations.

Authors:  X Hou; P L Breese; J M Douglas
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

4.  Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.

Authors:  Teena Mohan; Jongrok Kim; Zachary Berman; Shelly Wang; Richard W Compans; Bao-Zhong Wang
Journal:  J Control Release       Date:  2016-05-10       Impact factor: 9.776

5.  Detection of antibodies to caprine arthritis-encephalitis virus by protein G enzyme-linked immunosorbent assay and immunoblotting.

Authors:  R Zanoni; A Krieg; E Peterhans
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

6.  Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection.

Authors:  J V Giorgi; P G Nishanian; I Schmid; L E Hultin; H L Cheng; R Detels
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

7.  Oral fluids as an alternative to serum for measurement of markers of immune activation.

Authors:  P Nishanian; N Aziz; J Chung; R Detels; J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-07

8.  Organizing for ontological change: The kernel of an AIDS research infrastructure.

Authors:  David Ribes; Jessica Beth Polk
Journal:  Soc Stud Sci       Date:  2015-04       Impact factor: 3.885

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.